Cargando…
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known...
Autores principales: | Tai, Wanbo, He, Lei, Zhang, Xiujuan, Pu, Jing, Voronin, Denis, Jiang, Shibo, Zhou, Yusen, Du, Lanying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091888/ https://www.ncbi.nlm.nih.gov/pubmed/32203189 http://dx.doi.org/10.1038/s41423-020-0400-4 |
Ejemplares similares
-
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020) -
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020) -
MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023) -
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022) -
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection
por: Du, Lanying, et al.
Publicado: (2008)